FDA Rolls Back Lab Test Regulations After Court Vacatur
Published Date: 9/19/2025
Rule
Summary
The FDA is rolling back a recent rule about lab tests done in labs, called Laboratory Developed Tests (LDTs), because a court said so. This means the rules go back to how they were before May 2024. Labs and medical device makers should keep doing what they were doing before, with no new costs or changes for now.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Court vacates May 6, 2024 LDT rule
If you run a lab or make laboratory-developed tests (LDTs), a court vacated the FDA's May 6, 2024 amendment on March 31, 2025. The FDA has reverted the regulation text to how it existed before the May 2024 final rule.
No new costs or changes for now
If you operate a lab or manufacture LDTs, you should continue following the pre-May 2024 rules and expect no new costs or changes for now, per the FDA's implementation of the March 31, 2025 vacatur.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2025-18238 — Acceleration of Effectiveness of Registration Statements of Issuers With Certain Mandatory Arbitration Provisions
If a company’s registration statement includes a rule that investors must use arbitration to settle disputes, the SEC won’t slow down approving it. Instead, they’ll focus on whether the company clearly explains this arbitration rule in their paperwork. This means companies with these arbitration clauses can get their registrations approved just as fast as others, as long as they’re upfront about it.
Next: 2025-18243 — Airspace Designations; Incorporation by Reference Amendments
The FAA is updating its official airspace rules by adding some new changes to a key order, effective September 15, 2025. This affects pilots and air traffic controllers by keeping airspace info fresh and accurate. No extra costs are expected, just smoother skies ahead!